Search / Trial NCT00001436

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

Launched by NATIONAL CANCER INSTITUTE (NCI) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of December 05, 2024

Completed

Keywords

Hormone Interactions Igf I Metastatic Pediatric Recurrent

ClinConnect Summary

Osteosarcoma is the most common primary bone malignancy in childhood and adolescence. Its peak age of onset has suggested a possible contribution to the pathogenesis of the tumor by the endogenous hormonal milieu, which accompanies the adolescent growth spurt. In support of this, recent in vitro and in vivo laboratory investigators suggest that Insulin-like growth factor I (IGF I) may play an important role in the pathobiology of osteosarcoma. Somatostatin (and its longer-acting analogues) directly inhibits the pituitary release of growth hormone, thereby indirectly reducing the level of ci...

Gender

ALL

Eligibility criteria

  • • Must have been diagnosed with osteosarcoma by the age of 25 years.
  • • Patient must have a biopsy proven osteosarcoma and either: a) active tumor with no available standard therapy options; b) metastatic osteosarcoma at diagnosis, has completed therapy and has no evidence of active disease; or, c) is status-post any surgery for recurrent osteosarcoma, either local or metastatic recurrence, and is free of disease by CT scan.
  • • Measurable disease not required.
  • • Patients with serum creatinine \&lte; 2.0 mg/dL or creatinine clearance \&gte; 40 ml/min per 1.73m(2) (if serum creatinine is \&gte; 2.0 mg/dL).
  • • Patients with normal thyroid function.
  • • Patients with total bilirubin, SGOT and SGPT \< twice the upper limit of normal.
  • • Patients with normal direct bilirubin only if total direct bilirubin is abnormal.
  • • Patients with bone marrow criteria: ANC\>1500/mm(3) and platelet count \>100,000/mm(3).
  • • Patients without a history of insulin-dependent diabetes mellitus or current insulin requirement. Fasting morning blood glucose \<150 mg/dL.
  • • Patients with ECOG performance status of 0, 1 or 2 and a life expectancy of at least 8 weeks.
  • • Patients not on chemotherapy or radiation therapy within the past 2 weeks and recovered from the acute side effects of prior anti-neoplastic therapy.
  • • Patients with documented negative HIV serology within the past 6 months.
  • • Post-menarcheal patients must have documented negative urine and serum pregnancy test (B-HCG); when indicated, patient must be willing to take oral contraceptives or other appropriate contraceptives to avoid pregnancy during the period of treatment.
  • • Patient, parent or guardian must give informed consent.
  • • No pregnant or lactating women.
  • • No women of child-bearing potential who are unable or unwilling to use appropriate contraceptives during the period of treatment.
  • • No patients with uncorrected hypothyroidism.
  • • No patients with insulin-dependent diabetes mellitus or fasting blood glucose \&gte; 150 mg/dL.
  • • No patients with HIV infection.
  • • No patients with a history of thromboembolic events who require prophylaxis for thromboembolic events with anticoagulants once entry into Cohort III has begun.
  • • Patients with a history of symptomatic gallbladder disease must have had a cholecystectomy.

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials